$CODX
Co-Diagnostics, Inc. Stock $codx

$codx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040050 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$3.555M	$2.457M
YoY Change	153.67%	-51.77%
Cost Of Revenue	$2.968M	$255.8K
YoY Change	475.42%	-66.69%
Gross Profit	$587.3K	$2.201M
YoY Change	-33.69%	-49.12%
Gross Profit Margin	16.52%	89.59%
Selling, General & Admin	$5.921M	$5.052M
YoY Change	-10.02%	-8.35%
% of Gross Profit	1008.1%	229.5%
Research & Development	$6.179M	$5.789M
YoY Change	30.37%	14.91%
% of Gross Profit	1051.98%	262.97%
Depreciation & Amortization	$312.9K	$300.0K
YoY Change	4.77%	-4.15%
% of Gross Profit	53.27%	13.63%
Operating Expenses	$12.41M	$11.14M
YoY Change	6.83%	2.53%
Operating Profit	-$11.83M	-$8.936M
YoY Change	10.18%	36.73%
Interest Expense	$1.428M	$700.0K
YoY Change	456.03%	313.86%
% of Operating Profit
Other Income/Expense, Net		$840.2K
YoY Change		-72.54%
Pretax Income	-$10.84M	-$8.096M
YoY Change	-56.71%	132.93%
Income Tax	$3.834M	-$2.114M
% Of Pretax Income
Net Earnings	-$14.68M	-$5.982M
YoY Change	-33.0%	339.52%
Net Earnings / Revenue	-412.82%	-243.47%
Basic Earnings Per Share		-$0.20
Diluted Earnings Per Share	-$0.50	-$0.20
COMMON SHARES
Basic Shares Outstanding	30.58M shares	30.79M shares
Diluted Shares Outstanding		29.36M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.55M	$63.43M
YoY Change	-27.95%	-26.66%
Cash & Equivalents	$14.92M	$10.24M
Short-Term Investments	$43.63M	$53.19M
Other Short-Term Assets	$1.597M	$1.300M
YoY Change	109.82%	-1.23%
Inventory	$1.665M	$4.520M
Prepaid Expenses
Receivables	$303.9K	$806.7K
Other Receivables	$26.95K	$1.300M
Total Short-Term Assets	$62.14M	$71.31M
YoY Change	-32.99%	-30.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.036M	$2.808M
YoY Change	19.54%	15.18%
Goodwill
YoY Change
Intangibles	$26.40M	$26.48M
YoY Change	-1.36%	-1.47%
Long-Term Investments	$773.4K	$800.0K
YoY Change	14.97%	6.85%
Other Assets		$4.300M
YoY Change
Total Long-Term Assets	$33.18M	$37.37M
YoY Change	9.31%	-18.63%
TOTAL ASSETS
Total Short-Term Assets	$62.14M	$71.31M
Total Long-Term Assets	$33.18M	$37.37M
Total Assets	$95.32M	$108.7M
YoY Change	-22.56%	-26.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.482M	$1.416M
YoY Change	55.64%	-31.1%
Accrued Expenses	$2.173M	$1.827M
YoY Change	132.54%	20.83%
Deferred Revenue	$362.4K	$349.5K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.748M	$5.098M
YoY Change	48.38%	-15.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.559M	$4.100M
YoY Change	56.47%	32.84%
Total Long-Term Liabilities	$3.559M	$4.094M
YoY Change	-24.15%	-40.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.748M	$5.098M
Total Long-Term Liabilities	$3.559M	$4.094M
Total Liabilities	$9.307M	$9.192M
YoY Change	8.65%	-28.72%
SHAREHOLDERS EQUITY
Retained Earnings	$4.598M	$19.27M
YoY Change	-88.48%	-68.83%
Common Stock	$36.11K	$35.37K
YoY Change	3.9%	3.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$15.58M	$15.42M
YoY Change	9.6%	18.64%
Treasury Stock Shares
Shareholders Equity	$86.01M	$99.49M
YoY Change
Total Liabilities & Shareholders Equity	$95.32M	$108.7M
YoY Change	-22.56%	-26.49%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$14.68M	-$5.982M
YoY Change	-33.0%	339.52%
Depreciation, Depletion And Amortization	$312.9K	$300.0K
YoY Change	4.77%	-4.15%
Cash From Operating Activities	-$4.779M	-$6.590M
YoY Change	19.17%	-689.28%
INVESTING ACTIVITIES
Capital Expenditures	$464.6K	$240.0K
YoY Change	58.41%	-204.33%
Acquisitions
YoY Change
Other Investing Activities	$10.08M	$3.400M
YoY Change	-119.01%	-31.58%
Cash From Investing Activities	$9.615M	$3.170M
YoY Change	-118.04%	-33.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-159.7K	-160.0K
YoY Change	-86.89%	-98.46%
NET CHANGE
Cash From Operating Activities	-4.779M	-6.590M
Cash From Investing Activities	9.615M	3.170M
Cash From Financing Activities	-159.7K	-160.0K
Net Change In Cash	4.677M	-3.580M
YoY Change	-107.99%	-21.1%
FREE CASH FLOW
Cash From Operating Activities	-$4.779M	-$6.590M
Capital Expenditures	$464.6K	$240.0K
Free Cash Flow	-$5.243M	-$6.830M
YoY Change	21.85%	-606.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001692415
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax		usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments		usd
CY2023Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38148
	dei	Entity Registrant Name EntityRegistrantName	CO-DIAGNOSTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2609396
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 S. Foothill Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite D
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84109
	dei	City Area Code CityAreaCode	(801)
	dei	Local Phone Number LocalPhoneNumber	438-1036
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	CODX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30580904	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10239898	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	53188999	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58289066	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	806704	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	4520430	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2023Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	1245854	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1870419	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1290146	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	761187	usd
CY2023Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	18750	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	71310781	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	92733671	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2808339	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2539483	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4272002	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3032337	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	372115	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26479333	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2023Q3	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	778943	usd
CY2022Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	672679	usd
CY2023Q3	us-gaap	Assets Assets	108681735	usd
CY2022Q4	us-gaap	Assets Assets	123086281	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1416435	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	952296	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1826639	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934447	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	794516	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297209	usd
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	710651	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1689471	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	349499	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5097740	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3873423	usd
CY2023Q3	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1359725	usd
CY2022Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1181284	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2417987	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2250393	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50708	usd
CY2023Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	484332	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	1042885	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4094450	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4692864	usd
CY2023Q3	us-gaap	Liabilities Liabilities	9192190	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8566287	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35367100	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30658580	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34754265	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30872607	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	35367	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	34754	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4708520	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3881658	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	15416122	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	14211866	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	94983030	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88472935	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	612649	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	293140	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19274621	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	39931031	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	99489545	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108681735	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123086281	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2457098	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5094456	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3256861	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32816726	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	255772	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	767936	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1217108	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4965319	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	2201326	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	4326520	usd
	us-gaap	Gross Profit GrossProfit	2039753	usd
	us-gaap	Gross Profit GrossProfit	27851407	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1904395	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1889907	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5343692	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6014280	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3147753	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3622273	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9875613	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9012888	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5788789	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5037461	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16783892	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12698632	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	296340	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	312494	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	917596	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	984100	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	11137277	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	10862135	usd
	us-gaap	Operating Expenses OperatingExpenses	32920793	usd
	us-gaap	Operating Expenses OperatingExpenses	28709900	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8935951	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6535615	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30881040	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-858493	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	322877	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	298184	usd
	us-gaap	Interest Income Other InterestIncomeOther	717141	usd
	us-gaap	Interest Income Other InterestIncomeOther	371248	usd
CY2023Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	425446	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1254718	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2578	usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4044	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2578	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
CY2023Q3	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	140296	usd
CY2022Q3	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	2886734	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	1537373	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7079446	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-45865	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-129047	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	106264	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-256911	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	840176	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3059915	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3612918	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7055666	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8095775	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3475700	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27268122	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6197173	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2113581	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2114638	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6611712	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1470058	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5982194	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20656410	usd
	us-gaap	Net Income Loss NetIncomeLoss	7667231	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	33522	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	319509	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	33522	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	319509	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5948672	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1361062	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20336901	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7667231	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361300	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31321368	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29306572	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32109213	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361300	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31321368	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29306572	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33002539	shares
	us-gaap	Net Income Loss NetIncomeLoss	-20656410	usd
	us-gaap	Net Income Loss NetIncomeLoss	7667231	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	917596	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	984100	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6510708	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5138815	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	1537373	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7079446	usd
	CODX	Noncash Lease Expense NoncashLeaseExpense	36770	usd
	CODX	Noncash Lease Expense NoncashLeaseExpense	17193	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	1254718	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	106264	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-256911	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2578	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6689989	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3431286	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	326647	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	338057	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2320372	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12539461	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-151858	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-441786	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-790716	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3656463	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	349499	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-150000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	178441	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1822977	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1356330	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-802955	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17303239	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10578544	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	900704	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1134208	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	90279227	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6223740	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	83604933	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9950824	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5773590	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4861292	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	177870	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1204256	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	12994373	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1204256	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12816503	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12733905	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7099251	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22973803	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10239898	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81507983	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	49197	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4496239	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	673	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	218906	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3063782	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	681327	usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments	681728	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519994	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2168742	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	482196	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	178621	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5755391	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	110629770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2169801	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	555734	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	107366	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8918825	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103432378	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	103432378	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2172165	usd
CY2023Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	166326	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	33522	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5982194	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5982194	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	99489545	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	99489545	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475100	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50001	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1375097	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11714595	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	147714793	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27869	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1533284	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	480776	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2599478	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686304	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470940	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470940	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2230434	usd
CY2022Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	10394895	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	134945417	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	134945417	usd
	CODX	Reclassifications Policytext Block ReclassificationsPolicytextBlock	<p id="xdx_848_ecustom--ReclassificationsPolicytextBlock_zPJceCRBYmog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zJ0OmyuEni8j">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4231877	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3425173	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	806704	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6552249	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3098526	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	4520430	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	788104	usd
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	3732326	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1327264	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3983209	usd
CY2023Q3	CODX	Grant Funding Revenue GrantFundingRevenue	2300000	usd
	CODX	Grant Funding Revenue GrantFundingRevenue	2300000	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	300000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5788789	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16783892	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5037461	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12698632	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zh7hTxp1qq46" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zOYmBpi7FPEh">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which were each responsible for generating <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJ1aic3wwIq5" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z8f70WMT9Ena" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the three and nine months ended September 30, 2023. Three customers accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcXcRxqoU1pk" title="Concentration risk percentage">47</span>% of product revenue for the three months ended September 30, 2023, and two customers accounted for approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIVIQKBUzay" title="Concentration risk percentage">28</span>% of product revenue for the nine months ended September 30, 2023. One granting agency accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwvgi28uwLk9" title="Concentration risk percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVblAUvO0Dvc" title="Concentration risk percentage">94</span></span>% of grant revenue for the three and nine months ended September 30, 2023. One customer accounted for approximately<span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNawVgko3Red" title="Concentration risk percentage"> 52</span>% of product revenue for the three months ended September 30, 2022, and two customers accounted for approximately<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zftdIAoApTCc" title="Concentration risk percentage"> 47</span>% of product revenue for the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers accounted for more than<span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z6C5tTE97Bbj" title="Concentration risk percentage"> 10</span>% of accounts receivable at September 30, 2023 and three customers accounted for more than <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zK7sP0SWdeAj" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2022. These customers together accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zvVgSanDtFje" title="Concentration risk percentage">71</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zp5TU8GPUPMi" title="Concentration risk percentage">37</span>% of accounts receivable at September 30, 2023 and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
CY2023Q3	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	62615573	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	813324	usd
CY2023Q3	us-gaap	Trading Securities TradingSecurities	63428897	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10239898	usd
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities	53188999	usd
CY2022Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	80873628	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	389241	usd
CY2022Q4	us-gaap	Trading Securities TradingSecurities	81262869	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	58289066	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-715667	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26479333	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-426667	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	75665	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	302668	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	378333	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2732356	usd
	CODX	Contingent Considered Issued For Business Acquisitions ContingentConsideredIssuedForBusinessAcquisitions	-1537373	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1194983	usd
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y3M18D
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2457098	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5094456	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3256861	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	32816726	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2457098	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5094456	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3256861	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	32816726	usd
	CODX	Increase Due To Prepayments From Customers IncreaseDueToPrepaymentsFromCustomers	19620	usd
	CODX	Increase Due To Prepayments From Grants Received IncreaseDueToPrepaymentsFromGrantsReceived	329879	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	349499	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5982194	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20656410	usd
	us-gaap	Net Income Loss NetIncomeLoss	7667231	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361300	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31321368	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29306572	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32109213	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	893326	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361300	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31321368	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29306572	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33002539	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2631642	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1385869	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M17D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y1M17D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1040572	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2023Q3	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M17D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.81
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	2.43
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2023Q3	CODX	Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice	8.81
CY2023Q3	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	0.92
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P3Y2M12D
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2172165	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2230434	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6510708	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5138815	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2113581	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.261	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6611712	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.242	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2114638	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1470058	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	244941	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	529089	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	38110	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	192261	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	283051	usd
	us-gaap	Lease Cost LeaseCost	721350	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	233826	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	966451	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	987252	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	682806	usd
CY2023Q3	CODX	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	542512	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3412847	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	367938	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3044909	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	794516	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2250393	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	680580	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062	pure
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	30000000.0	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	3881658	shares
	CODX	Repurchases Of Common Stock RepurchasesOfCommonStock	826862	shares
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4708520	shares
CY2023Q4	CODX	Grant Funding Revenue GrantFundingRevenue	9000000.0	usd

Files In Submission

Name	View Source	Status
codx-20230930_cal.xml	Edgar Link	unprocessable
0001493152-23-040050-index-headers.html	Edgar Link	pending
0001493152-23-040050-index.html	Edgar Link	pending
0001493152-23-040050.txt	Edgar Link	pending
0001493152-23-040050-xbrl.zip	Edgar Link	pending
codx-20230930.xsd	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
codx-20230930_def.xml	Edgar Link	unprocessable
codx-20230930_lab.xml	Edgar Link	unprocessable
codx-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CODX
Co-Diagnostics, Inc. Stock $codx

2023 Q4 Form 10-Q Financial Statement

#000149315223040050 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX Co-Diagnostics, Inc. Stock $codx

2023 Q4 Form 10-Q Financial Statement

#000149315223040050 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX
Co-Diagnostics, Inc. Stock $codx